WVE ▲ +0.7% - Wave Life Sciences, Inc. $WVE - Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity Wave Life Sciences initiated a Phase 2a trial combining its GalNAc-siRNA candidate WVE-007 with Tirzepatide, Eli Lilly's obesity drug, marking a strategic advancement in the company's pipeline. The modest 0.7% gain suggests investors viewed the combination study as a positive development, though the market response remained measured, possibly reflecting the early-stage nature of the trial or existing investor positions. 23-SEP-2026 07:30 AM ET